MET and neoplasm: In a subsequent Phase II trial for advanced or metastatic NSCLC patients treated with glesatinib as monotherapy, the MET activating mutations in tumor tissue group had a progression-free survival (PFS) of 3.95 months and an ORR of 10.7%, while the MET gene amplifications in tumor tissue group had a PFS of 4.84 months and an ORR of 15% (NCT02544633).